RxDoctor Payments Data

Leea Arsenault, NP

Registered Nurse · Toms River, NJNPI 1750642062

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.3% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Among registered nurse clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,129in general payments, 2019–2025

Across 293 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$544
  • Pfizer$407
  • Lilly USA, LLC$402
  • Regeneron Healthcare Solutions, Inc.$331
  • AbbVie$308
  • Novartis$257
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,85593%
  • Education$2757%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,129 in reported general payments places this provider in the 95th percentile of 83 registered nurse providers in New Jersey.

See all registered nurse providers in New Jersey

Medicare billing

Part B allowed, 2024
$105,109
Medicare patients
370
Services billed
1,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$80,640
EnstilarCalcipotriene/Betamethasone13$17,901
Clobetasol Propionate52$1,888
Ketoconazole114$1,371
Triamcinolone Acetonide95$1,150
Fluorouracil11$1,016
Tacrolimus15$1,008
Fluocinonide24$904
Clobetasol EmollientClobetasol Propionate/Emoll12$644
Fluticasone Propionate37$608
Halobetasol Propionate17$580
Metronidazole21$543
Ciclopirox13$517
Doxycycline Hyclate61$513
Betamethasone Dipropionate14$468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Enstilar$226$17,90113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 83 registered nurse providers in New Jersey.

Other registered nurse in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →